Investor Presentation
7
Investor presentation First six months of 2022
Novo NordiskⓇ
GLP-1 performance drives Diabetes care sales growth in
International Operations and Ozempic® is now the leading brand
Reported Diabetes care sales and growth per IO geography
Number of
DKK
billion
■Insulin GLP-1 Growth at CER
GLP-1 patients and value market share in IO
patients (millions) Class volume growth >50%
10%
4
Value
market share
75%
25
53%
61.3%
60%
20
20
3
52.0%
12%
Geographical regions
15
39.0% 45%
36.2% 30%
19.1%
15%
3.3%
0%
May
2022
2
35%
10
-5%
25%
-7%
83%
92%
1
5
1%
-17%
1%
0
0
IO
EMEA
China
ROW
May
2020
May
2021
Ozempic
―dulaglutide
-RybelsusⓇ
-NN GLP-1
Source: Quarterly company announcement, IQVIA MAT, May 2022 (Spot rate). Note that the market share and patient numbers are based on countries with IQVIA coverage. GLP-1 market volume growth is calculated as a 12-month MAT
IO: International Operations; NN: Novo Nordisk; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; Row: Rest of World
GLP-1 patients
-VictozaⓇView entire presentation